Frederick Westhorpe serves as the Director of Discovery Pharmacology at COMPASS Pathways, where he is at the forefront of pioneering research aimed at transforming the landscape of mental health treatment. With a robust background in biochemistry and a decade of experience in the San Francisco...
Frederick Westhorpe serves as the Director of Discovery Pharmacology at COMPASS Pathways, where he is at the forefront of pioneering research aimed at transforming the landscape of mental health treatment. With a robust background in biochemistry and a decade of experience in the San Francisco Bay Area, particularly at Stanford University, Frederick brings a wealth of expertise in pharmacology and drug discovery to his role. His current focus is on preclinical pharmacology within the R&D division, where he leads innovative projects exploring the therapeutic potential of psilocybin for treatment-resistant depression. This groundbreaking work is part of COMPASS's broader mission to accelerate patient access to evidence-based innovations in mental health care.
Frederick's passion for advancing human health is evident in his commitment to leveraging cutting-edge technologies and methodologies, such as high content screening and confocal microscopy, to drive ambitious research initiatives. His proficiency in data analysis and epigenetics allows him to uncover novel insights that could facilitate a paradigm shift in how mental health disorders are treated. As COMPASS Pathways continues to expand its clinical programs, Frederick is instrumental in identifying and developing new therapeutic strategies to address unmet needs in mental health, ensuring that the company remains at the forefront of scientific advancement in this critical field. His dedication to fostering a collaborative research environment further enhances the potential for impactful discoveries that could significantly improve the lives of individuals struggling with mental health challenges.
